Rare case of hemangiopericytoma responds to sunitinib
Translational Research, ISSN: 1931-5244, Vol: 151, Issue: 3, Page: 129-133
2008
- 28Citations
- 12Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations28
- Citation Indexes28
- CrossRef28
- 25
- Captures12
- Readers12
- 12
Article Description
Hemangiopericytoma (HP) is a rare mesenchymal tumor associated with the capillary wall. We describe a 62-year-old man with a 20-year history of recurrent metastatic HP, in which a favorable clinical benefit was observed with sunitinib, an oral VEGFR, and PDGFR kinase inhibitor. Disease progression was evident during the 3 months before starting sunitinib therapy. Radiologic evaluation indicated that metastatic lesions in the lungs and pelvis remained stable during the 6 months on sunitinib therapy. Histologic analysis of the tumor 3 weeks after active sunitinib therapy did not reveal tumor necrosis, but recanalized thrombi within tumor blood vessels indicated previous tumor insult. Additional studies are warranted to confirm the possible effects of sunitinib in controlling widespread metastatic HP.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1931524407003374; http://dx.doi.org/10.1016/j.trsl.2007.12.007; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=39149100614&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/18279811; https://linkinghub.elsevier.com/retrieve/pii/S1931524407003374; https://dx.doi.org/10.1016/j.trsl.2007.12.007
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know